Physician profile
Moshe Kerstein
NPI 1831269398
$3,461.64
in general payments reported to CMS, 2019-2025
16 companies · $269 in 2025
The $269 reported for 2025 was less than what a typical Pulmonary Disease provider received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $712 · 2020: $631 · 2021: $701 · 2022: $609 · 2023: $496 · 2024: $43.68 · 2025: $269.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $809.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $808.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,378.74 | 2019-2023 | Jardiance |
| Astrazeneca Pharmaceuticals LP | $591.50 | 2019-2023 | Breztri |
| Glaxosmithkline, LLC. | $455.86 | 2019-2023 | Trelegy Ellipta |
| Pfizer INC. | $269.05 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $249.81 | 2019 | |
| E.R. Squibb & Sons, L.L.C. | $153.19 | 2024-2025 | Camzyos |
| Amgen INC. | $71.31 | 2023 | Tezspire |
| Insmed, INC. | $70.14 | 2025 | Arikayce |
| Merck Sharp & Dohme LLC | $53.23 | 2020-2021 | |
| Takeda Pharmaceuticals U.S.A., INC. | $41.74 | 2024-2025 | Vpriv |
| Eisai INC. | $23.47 | 2021 | |
| Exact Sciences Corporation | $22.66 | 2025 | Cologuard Collection Kit |
| Actelion Pharmaceuticals US, INC. | $22.23 | 2023 | Opsumit |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $21.42 | 2019 | |
| Nestle Healthcare Nutrition INC. | $18.92 | 2023 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi Pasteur INC. | $18.37 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Moshe Kerstein listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.